SAG
MAZE

SageView Advisory Group’s Maze Therapeutics MAZE Stock Holding History

SageView Advisory Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.24K Buy
+54
New +$1.86K ﹤0.01% 2208

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

SageView Advisory Group's MAZE Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Maze Therapeutics (MAZE) in Q4 2025: 54 shares worth $2.24K. The stake represents ﹤0.01% of the portfolio and ranks #2208 among its holdings.

143 funds tracked by Wall St. Rank hold MAZE as of Q4 2025.

  • SageView Advisory Group held 54 shares of Maze Therapeutics worth $2.24K as of Q4 2025.
  • Maze Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Maze Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2208 holding.
  • 143 funds tracked by Wall St. Rank held Maze Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.